Correlation of BAG-3 and heat shock protein 70 with CD30 expression in T-cell lymphomas.
T-cell lymphomas are aggressive lymphomas with decreased prognosis and resistance to therapy. BAG-3 and heat shock protein 70 (HSP70) function in chemotherapeutic resistance and cellular survival. Expression of BAG-3 has not been investigated in T cell lymphomas. We investigated fifty cases including benign, systemic and cutaneous T cell lymphomas. Benign T cells were negative for BAG-3 and HSP70 immunohistochemical staining. BAG-3 expression correlated with increased HSP70 expression in a subset of systemic T cell lymphoma cases co-expressing the CD30 antigen. Correlation between BAG-3, HSP70 and CD30 expression was not seen in cutaneous T cell lymphoma cases. However, these cases showed a significant increase in BAG-3 staining when compared to CD30 negative systemic T cell lymphoma cases. The differential protein expression profile of BAG-3 and HSP70 may indicate a specific role for these proteins and the ubiquitin-proteasome system/autophagy in T cell lymphomas which may help guide future targeted therapy.
Department of Pathology and Laboratory Medicine, Mayo Clinic, Jacksonville, FL.
L
L
Jiang
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN.
Z
Z
Zhao
Department of Pathology and Laboratory Medicine, Mayo Clinic, Jacksonville, FL.
D M
DM
Menke
1] Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN [2] Department of Pathology, Virginia Commonwealth University, Richmond, VA.
K A
KA
Rizzo
D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D016227:Benzoquinones / Q000627:therapeutic use; D000069286:Bortezomib / Q000627:therapeutic use; D017252:CD3 Complex / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015870:Gene Expression; D020869:Gene Expression Profiling; D018840:HSP70 Heat-Shock Proteins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D017730:Ki-1 Antigen / Q000096:biosynthesis*; D047029:Lactams, Macrocyclic / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000473:pathology*; D046888:Tissue Array Analysis; D055815:Young Adult
D048868:Adaptor Proteins, Signal Transducing; D051017:Apoptosis Regulatory Proteins; C414431:BAG3 protein, human; D016227:Benzoquinones; D017252:CD3 Complex; D018840:HSP70 Heat-Shock Proteins; D018841:HSP90 Heat-Shock Proteins; D017730:Ki-1 Antigen; D047029:Lactams, Macrocyclic; C112765:tanespimycin; D000069286:Bortezomib